In stock
Pentadecapeptide derived from the gastric protective protein BPC
BPC-157 10 mg
A fifteen-amino-acid sequence isolated from human gastric juice, where it forms part of a mucosa-protecting protein. Unlike most peptides it resists degradation in acid, a property that explains why it is also investigated by the oral route.
- CAS
- 137525-51-0
- Formula
- C62H98N16O22
- Molecular weight
- 1419.5 g/mol
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Purity
- ≥ 98% verified by HPLC
- Presentation
- Amber glass vial with lyophilized powder, vacuum sealed.
- Includes 3 ml BAC waterIn the same box, at no cost.
How it works
- Activates the VEGFR2-Akt-eNOS pathway, promoting new vessel formation in injured tissue.
- Modulates the nitric oxide axis in both excess and deficit, described as a stabilising rather than a stimulating effect.
- Increases growth factor receptor expression in tendon fibroblasts, accelerating their migration.
- Interacts with the dopaminergic and serotonergic systems in animal models of stress.
Qué dice la evidencia
- Review of the preclinical evidence on tissue repair and safety of the pentadecapeptide.
- Faster closure of tendon defects and increased fibroblast migration versus control.
Route described in the studies
- Route
- Subcutaneous. Localised protocols apply it near the anatomical site of injury.
- Preparation
- Reconstitute with BAC WATER against the vial wall. Swirl without shaking until fully dissolved; the resulting solution is clear.
- Application site
- Alternate the application site with each dose.
Documented effects
- Mild discomfort or redness at the application site
- Transient dizziness reported in isolated cases
- The long-term human safety profile is not established
When it is not used
- Active or recent neoplasia, given the compound's angiogenic activity
- Pregnancy and breastfeeding, no data available
Storage
- Lyophilised
- 2 to 8 °C protected from light. Stable up to 24 months unopened.
- Reconstituted
- 2 to 8 °C. Use within 30 days.
- Shipping
- Stable at ambient temperature in lyophilized form during shipping.
Preguntas frecuentes
Is the oral route equivalent to subcutaneous?
No. Gastric stability allows oral study, but documented systemic exposure differs and doses are not interchangeable.
Does it have to be applied near the injury?
The literature describes both systemic and local effects. Applying it nearby is a protocol practice, not a demonstrated requirement.
Research use only
Este compuesto se vende únicamente para investigación de laboratorio y desarrollo analítico. No es un medicamento, no está aprobado por ninguna autoridad sanitaria, y no se vende para diagnosticar, tratar, curar ni prevenir ninguna enfermedad. No es apto para consumo humano ni animal.